Anubis Somatropin 1 x 100 IU

What is somatropin?

Somatropin is the international generic name for recombinant human growth hormone (rhGH) — a protein molecule produced by genetic engineering that has an identical amino acid sequence to the naturally occurring growth hormone produced by the pituitary gland. The molecule consists of 191 amino acids in a continuous polypeptide chain with two intramolecular disulfide bridges and has a molecular weight of approximately 22 kilodaltons. It is produced by expressing the rhGH gene in bacterial or mammalian cell systems (most commonly E. coli or culture of mammalian cells), after which the protein is purified and freeze-dried into an injectable form.

The pharmaceutical presentation 1×100 IU means a single vial of reconstituted powder containing 100 international units — where 1 milligram of purified somatropin corresponds to approximately 3 IU. Multi-dose vials of this type are used clinically to simplify administration for longer treatment periods and require continuous refrigerated storage after reconstitution. Bacteriostatic water with benzyl alcohol is used as a reconstitution solution because it allows multiple withdrawals from the bottle without risk of contamination during a limited period of time.

Before recombinant technology became available in the 1980s, growth hormone was extracted from autopsy material—specifically, pituitary glands from deceased humans. That method was abandoned after cases of Creutzfeldt-Jakob disease were linked to contaminated preparations. Genentech's Protropin, approved by the FDA in 1985, became the first commercially available recombinant variant, and in 1987 the completely nature-identical 191-amino acid form was introduced under the trade name Humatrope. The approved clinical indications include deficiency conditions in children (idiopathic growth hormone deficiency, Turner syndrome, Prader-Willi syndrome) and adult growth hormone deficiency.

How does somatropin work?

After subcutaneous injection, somatropin is absorbed from the injection depot into the blood with a bioavailability of around 70–80 percent and a plasma half-life of 2–4 hours. However, the biological half-life is significantly longer because the hormone primarily acts by inducing the formation of a secondary messenger hormone, IGF-1, whose serum levels persist significantly longer than the administered somatropin.

At the cellular level, somatropin binds to the growth hormone receptor (GHR), a transmembrane protein receptor expressed on most tissues but in highest density in the liver. The binding triggers dimerization of two receptor molecules, which activates the intracellular kinase JAK2. JAK2 phosphorylates the transcription factor STAT5b, which translocates to the cell nucleus and directs the transcription of target sequences — of which the IGF-1 gene is central. The liver is the largest producer of circulating IGF-1, but muscle, cartilage and bone also produce local IGF-1 which contributes to the paracrine effects.

Somatropin also has direct effects that are not mediated via IGF-1. The hormone is lipolytic — it stimulates the breakdown of triglycerides in adipose tissue via activation of hormone-sensitive lipase. Glucose metabolism is directly affected because somatropin is insulin antagonistic and can raise blood glucose with heavy exogenous administration, an effect that is central to the diabetogenic profile and requires attention during prolonged treatment.

What can somatropin potentially affect?

In pharmacological literature from decades of clinical use in growth hormone deficiency as well as in epidemiological research, several physiological systems reappear where somatropin leaves a clear imprint:

• Growth and linear height increase — in children with open epiphyses, somatropin via IGF-1 stimulates chondrogenesis in the growth zones and increases the linear growth rate.

• Protein metabolism — the nitrogen balance becomes positive, the synthesis of muscle protein increases and the breakdown decreases, both via direct influence and via IGF-1.

• Lipid metabolism — the hormone has a pronounced lipolytic effect, especially on visceral and subcutaneous fat, with a consequent decrease in total fat mass during prolonged treatment.

• Connective tissue and skin — collagen synthesis increases in skin, cartilage and tendons, a phenomenon documented in the treatment of adults with growth hormone deficiency.

• Glucose metabolism — insulin sensitivity may decrease and fasting blood glucose may rise, requiring special attention in individuals with predisposing risk factors.

• Water and electrolyte balance — sodium and water retention is characteristic during the initiation phase and explains phenomena such as peripheral edema and carpal tunnel symptoms.

Potential side effects of somatropin

The side effect profile of somatropin is well established from decades of clinical use and from recent epidemiological studies. The profile is dose-dependent — at replacement doses in GH-deficient patients, adverse effects are relatively rare, but at supraphysiological doses, the risk of multiple reactions rises markedly. Multi-dose vials also add a risk of contamination and stability-related problems if storage conditions after reconstitution are not kept within recommended limits.

• Water and electrolyte balance — peripheral edema, facial edema, carpal tunnel syndrome due to fluid retention in the tissues surrounding nerve canals, and joint and muscle pain during the initial phase.

• Glucose metabolism — impaired insulin sensitivity, hyperglycemia and increased risk of type 2 diabetes, especially with prolonged exposure to high doses.

• IGF-1 mediated effects — with greatly elevated IGF-1 levels, acromegaly-like changes may occur: growth of hands, feet and jaw, changes in facial features, and organomegaly.

• Cardiovascular effects — left ventricular hypertrophy, increased blood pressure and edema are documented at supraphysiological exposure.

• Musculoskeletal — joint pain, muscle pain, stiffness of hands and joints, and risk of slippage of the epiphysis of the femoral head in children during growth.

• Tumor-related — the potential link between high IGF-1 levels and certain cancers (colorectal cancer, prostate cancer, breast cancer) is a key long-term concern that requires continuous monitoring in at-risk individuals.

• Local — redness, itching and lipoatrophy at the injection site, often mild and usually quickly transient.

The overall side effect picture of somatropin — fluid retention, glucose metabolic impact, IGF-1-mediated structural effects and theoretical tumor-related risk — means that clinical use requires close medical follow-up with laboratory controls (IGF-1 levels, fasting glucose, HbA1c, thyroid function) and an individual assessment of the risk-benefit balance.